← Back to all trials
Active Not Recruiting
NCT04335058
Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Conditions: Iron Deficiency Anemia, Chronic Liver Failure
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: Yes
Phase: NA
Enrollment: 130
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Location: Postgraduate Institute of Medical Education and Research Chandigarh
Summary
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease. Lactoferrin is a first line defence protein for protection against microbial infections and subsequent development of systemic disease as seen with systemic inflammatory response syndrome (SIRS) and sepsis. Lactoferrin with iron has been shown to be efficacious with anemia in chronic disease, in pregnancy and in cancer patients with fewer side effects than oral iron alone. High exposure to iron is associated with increased inflammation which is associated with worse cardiovascular outcomes. Lactoferrin can help reduce the total iron dose and hepatic inflammation.
Eligibility Criteria
Inclusion Criteria:
1. Age 18-75 years
2. Either gender
3. Patients with chronic liver disease with iron deficiency anemia with transferrin saturation\
Source: ClinicalTrials.gov (NCT04335058). StuddyBuddy aggregates publicly available trial information.
